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Background: The tachykininergic neurotransmitters have been proved to be involved in the inflammatory progress
and chronic pain in series of disease. The present study was undertaken to evaluate the levels of substance P (SP)
and its receptors NK-1 receptor (NK-1R) in both serum and synovial tissues of hip joint from patients with different
stages of DDH, and to detect the possible correlation of serum SP levels with pain sensation and dysfunction of the
hip joint.
Methods: SP levels in serum and synovial tissues from patients with DDH and DDH combined with osteoarthritis
(DDH&OA) group were compared through immunohistochemistry (IHC), ELISA, and 2-step acetic acid extraction
method respectively. Expression of NK-1R in synovial tissues was compared through IHC, quantitive Real-Time PCR
(QRT-PCR) and Western-Blot. The severities of pain sensation and the functional activities of hip joint were assessed
by Visual analogue scale (VAS) and Harris hip score (HHS). Correlations of serum SP levels with VAS, HHS and
erythrocyte sedimentation rate (ESR) were evaluated respectively in these groups.
Results: Significantly elevated serum SP levels were detected in group of DDH and DDH&OA compared to that in
normal group. IHC, QRT-PCR as well as tissue Elisa showed that SP levels in synovial tissue of DDH&OA group is
stronger than that in DDH group. Serum SP levels in each group have no gender differences. The enhanced SP
levels in synovial tissue mainly came from the segregation of peripheral nerve endings. Serum SP correlated with
VAS and HHS in patients with DDH&OA (Male + Female). Serum SP correlated with HHS in patients with DDH
(Male). Serum SP levels also correlated with erythrocyte sedimentation rate (ESR) in patients with DDH&OA
(Male + Female). Up-regulated expression of NK-1R was also observed in synovial tissue of patients with DDH&OA
compared to patients with DDH, through western-blot, IHC, and QRT-PCR.
Conclusions: These findings indicated that the increasing SP levels in serum and synovial tissues, observed from
patients with DDH to patients with DDH&OA, might associate with the loss of function and chronic pain sensation
in hip joint. SP along with its receptors NK-1R might be involved in the progression of DDH into DDH&OA. In the
future, inhibitors of SP as well as NK-1R may represent a novel pharmacotherapy target for pain relieving,
inflammation alleviating and joint degeneration delaying for patients with DDH.
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Developmental dysplasia of the hip (DDH), caused by de-
velopmental disorder of hip joint, results in shallow acet-
abulum, slacking joint capsule and subluxation of femoral
head which always lead to chronic pain as well as joint
dysfunction. The incidence rate of female and male with
DDH is approximately 4–10:1 in different countries [1,2].
The pathogenesis of DDH includes: susceptibility to the
X chromosome, genetic mutation, breech presentation,
swaddling position, and mechanical factors of hip joint
during acquired environment [3-5]. Besides, DDH is often
accompanied by series of morphological and anatomic
changes in hip joint, which bring about joint space
narrowing, articular surface abrasion, secondary osteo-
arthritis, synovial hyperplasia, and cystic change in sub-
chondral bone [6,7].
Pain in hip joint is a very common symptom for DDH,
being related to both motion and rest. Furthermore, the
degree of pain sensation is always associated with the pro-
gress of degeneration in hip joint according to clinical ob-
servations. However, so far, pathophysiologic mechanisms
of pain in DDH are not yet clear. According to the known
theories, femur acetabulum impingement, abrasion of ar-
ticular surface and labrum injuries might all contribute to
the occurrence of pain in hip joint [8,9].
Currently, the roles of tachykinin family and associated
mediators played in pain and inflammation, have attracted
increasing consensus in the field of molecular-biology on
clinical disease [10,11]. Among these neuropeptides, sub-
stance P (SP) along with its specific receptors NK-1R were
deemed as crucial factors in pain induction, which have
been proved in both human and rat model of knee os-
teoarthritis and rheumatoid arthritis [12-14]. Besides, the
up-regulation of SP and calcitonin gene-related peptide
(CGRP) was observed in hip joint capsule, synovium and
subchondral bone in patients with osteoarthritis [15,16].
On the other hand, being the member of tachykinin
family, SP is mainly secreted by sensory neurons in both
central and peripheral nerve systems [17], which indicated
that these neurotransmitters probably play a vital role in
joint pain mediation and transmission [18]. However, up
to now, the investigation of occurrence and transmission
of pain sensation in hip joint of DDH is still limited.
Therefore, this study was designed to detect the level of
SP and its receptors NK-1R in both serum and synovium of
hip joint in patients with DDH and DDH&OA. In addition,
we also want to investigate the main source of SP in syno-
vium, and the correlation of SP with chronic pain sensation
and the function of hip joint in different stages of DDH.
Methods
Patients and materials
Clinical data and samples included in this study were ob-
tained from patients underwent surgery treatment in ourinstitution between March 2011 and December 2012. 45
hips in patients (ranges: 35–48 years, mean: 40.4 years) with
chronic osteoarthritis combined with DDH (Crowe:I ~ III)
were set to DDH&OA. Including criteria were osteoarth-
ritis secondary to DDH, severe degenerative arthritis of
grade 4 in the classification of Kellgren and Lawrence
[19,20]. 56 patients with DDH (Crowe:I ~ III, ranges:
21–34 years, mean: 28.5 years) which defined as the hip
having a sharp angle <45°and centre edge(CE) angle <20°
[21,22] were included in this cohort. Severe pain sensation
and dysfunction in hip joint were common performances
for patients in both of these groups. Besides, 31 normal
volunteers (ranges: 22–38 years, mean: 33 years) were also
recruited in this study to serve as control group.
Synoviums in hip joint were obtained from patients
with DDH&OA (n = 35), DDH (n = 20) separately, as
shown in Table 1. In our study, patients with DDH&OA
were included and served as the advanced stage of DDH,
which help to investigate the content of SP and its re-
ceptors NK-1R in different stages of DDH. In order to
decrease the effect from age and sex, we recruited the
participants roughly the age and acquired the synovial
tissues for research mainly from female patients.
The diagnosis of DDH was based on impingement test
as well as Sharp, CE angles in pelvic anteroposterior radio-
graph by chief physician (Dr Chen) in clinic. Clinical and
laboratory data for the entire groups are presented in
Table 1. Variables such as erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP) was measured by cli-
nical standard technology. Synovial tissues of hip joint in
DDH&OA were acquired from the operation of Total hip
joint arthroplasty (THA). Synovial samples in DDH were
obtained during the operation of periacetabular osteotomy
(PAO) and osteochondrocyte plasty (OCP) for patients
with testify of opening joint capsule, which is characteris-
tic in our department [23,24]. Samples of synovial in fossa
acetabuli collected from operation were cut into pieces
of 1 × 1 cm2 and immerged into RNA Later (Ambion
AM7021 USA) for 12 hs and then stored at −80°C for
RNA and protein extraction.
Criteria for exclusion
Patients recruited in this study had no secondary osteo-
arthritis (OA) as a consequence of inflammation, rheu-
matism, osteonecrosis, trauma, gout or tumor. Kidney or
thyroid insufficiency was also an exclusion criterion. Drug
therapies with OPIATES or NSAIDS were not allowed.
Besides, patients with DDH subsequent by slipped epiphy-
sis, traumatic osteoarthritis and those who had expe-
rienced orthopedic hip surgery were also excluded.
Ethical justification
The study was performed based on the recommenda-
tions from the Declaration of Helsinki and was approved
Table 1 Data and clinical details of patients and normal people recruited in this study
DDH&OA DDH Normal
Number 45 56 31
Ages (yrs) 40.4 ± 5.3 (35-48) 28.5 ± 6.4 (21-34) 33 ± 4.5 (22-38)
Female/Male 31/14 48/12 17/14
BMI (kg/m2) 23.5 ± 1.3 22.7 ± 0.8 22.2 ± 1.1
Durations (yrs) 3.8 ± 0.5 1.3 ± 0.4 —
CRP (mg/l) 8.4 ± 2.4*Δ 4.7 ± 1.5 2.4 ± 0.7
ESR (mm/1st h) 16.8 ± 4.6* 12.3 ± 3.6* 6.2 ± 1.6
Harris hip score 37 ± 6.4**# 75.7 ± 8.3* 96 ± 2.5
Visual analogue score 5.7 ± 2.4Δ 3.2 ± 1.8 —
Synovial sample 35/45 20/56 —
Blood sample 40/45 40/56 31
BMI Body mass index, CRP C-reactive protein, ESR Erythrocyte sedimentation rate. Data are given as mean ± standard deviation (SD). *P < 0.05 and **P < 0.01
compared to data in normal group. ΔP < 0.05 and #P < 0.01 compared to data in DDH group.
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School Medicine Affiliate Xinhua Hospital. Samples pre-
pared from operation were only for testing purposes, and
were acknowledged, consented, and signed by patients.
Quantification of substance P
Serum test
Collected blood samples were allowed to clot for at least
30 min and then centrifuged at 3000 r/min for 15 min to
obtain serum. Serum samples were then kept at −80°C
before analysis. The concentration of SP in serum was
determined by an enzyme linked immunosorbent assay
(ELISA) kit (Cayman, catalog NO.583751, USA) according
to the manufacturer’s instructions, which provides accu-
rate measurements of SP with a working range of 1.5 to
500 pg/ml. It was verified by plenty of studies that the SP
antibody used here recognizes the intact peptide and
shows 100% specificity for SP, 93% for SP2-11, and 30%
for SP7-11 and was without cross-reactivity with neuro-
kinin A (2.7%) or neurokinin B (0.04%) [25,26].
Synovium test
The concentration of SP in synovium was evaluated by
the same ELISA Kit described above. SP levels in syno-
vium were extracted by two-step 2% acetic-acid [27,28].
Briefly, 10-50 mg synovial samples were obtained from
patients in separate groups as described in Table 1. We
cut the tissue into fragments of 1-4 mm3. The first ex-
traction was carried out by 1 ml 2% acetic-acid in 95°C
for 15 mins. The supernatant regarded as SP from nerve
endings was collected and then quickly frozen in −80°C.
The second extraction was implemented by 1 ml 2%
acetic-acid in 95°C for 45 mins. Supernatant was ex-
tracted and deemed as SP from non-nerve tissue or cells.
The levels of SP were normalized to the weight of the
tissue samples and expressed as pg/mg.Assessment of HHS and VAS score
Assessment of hip joint mobility was performed using
Harris hip score (HHS) by Dr Zhu. Along with HHS
score, a visual analogue scale (VAS) was also applied for
the assessment of pain severity of patients in separate
group. In order to determine VAS score, a 100-mm hori-
zontal line without scaling was designed in which 0
was marked as “no pain in hip” and 10 was marked as
“unbearable pain”. Patients were then instructed to place
a vertical mark reflecting their soreness severity. Scores
of both HHS and VAS in different groups were shown in
Table 1.
RNA isolation and quantitative real-time PCR (QRT-PCR)
Synovial tissues from fossa acetabuli were obtained during
operation of total hip arthroplasty (THA) or Bernese peri-
acetabular osteotomy (PAO) as previously described from
patients of 20 with DDH, 35 with DDH&OA. The tissues
were dissected into small pieces of 80 mg and immediately
frozen in liquid nitrogen. Frozen tissues (100 mg) were
grinded by mortars into granular powder and was dis-
solved in 2 ml volumes of Trizol reagent kit (Takara,
Code: D9108B, Japan). cDNA was synthesized from 2 mg
total RNA through reverse transcription using a TaKaRa
RNA PCR Kit (TaKaRa, DRR057A, Japan) according to
the manufacturer’s protocol. The sequences for primers
(TaKaRa, Biotechnology Co. Ltd, Japan) used to amplify
mRNA were as follows: TAC1R: F: 5′-GTCGTGTGCAT
GATCGAATGG-3′, R: 5′-TTGCTCGTGGTAGCGGTC
AG-3′; TAC1: F: 5′-GGTACGACAGCGACCAGATCA-
3′, R: 5′-CCCGTTTGCCCATTAATCCA-3′. Real-time
PCR was carried out using 200 ng of cDNA and Prime-
Script® RT-PCR Kit (Takara, DRR064A, Japan) in 96-well
plates in a ABI 7500 Sequence Detection System (ABI,
Co. Ltd, USA) according to the manufacturer’s instruc-
tions. Relative quantification of each gene was normalized
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to calculate relative gene expression levels as previously
described [29]. Results are presented as fold changes in
gene expression normalized to GAPDH and relative to
control conditions (DDH group). Data of each sample was
displayed on triplicate wells during every PCR amplifica-
tion circulation. Analysis of the results is based on at least
three individual experiments.
Immunohistochemistry and assessment
The synovial samples were dehydrated in a graded series
of ethanol and embedded in paraffin for immunohisto-
chemistry. The tissues were cut into sections measuring
5 um and were mounted on anti-off slides. Sections from
each group underwent citrate buffer antigen retrieval.
After incubated overnight with the primary antibody
NK-1R (1:1000) (Abcam, ab75516, UK) and substance
P(1:1000) (Abcam, ab14184, UK), slides were rinsed in
phosphate buffer saline (3×5 minutes) and incubated
with biotinylated secondary antibody (Dako, Ely, UK).
Finally, streptavidin-biotin complex (1:2000) (Amersham
Life Science Inc, USA) was used for the visualization of
the immunoreactions. From every synovium (8 per group),
two sections were acquired at different depths and eight
microscopic fields from each section were photographed
and analyzed. Thus, in every synovial sample of separate
group, 16 microscopic fields were collected. Images of the
microscopic fields were captured by a camera (DEI 750,
Optronics Engineering, USA) attached to the microscope.
The immune activity was measured as the area in mm2
using the software (Image-Pro plus 6.0, USA) as pre-
viously described [30]. The results were expressed as the
positive staining area (mm2) in relation to the total area of
each microscopic field.
Western-blot analysis
Synovial samples of different groups (150 mg/sample)
were grounded into powder with liquid nitrogen. Total
protein was extracted using a Western & IP Cell Lysis
Kit (Beyotime, Shanghai, China). The concentration of
protein in the cell lysate was determined using a mi-
croplate reader (Thermo, Finland) according to the
manufacturer’s protocol. For each sample, the whole cell
extracts equivalent to 40 mg total protein which were
loaded into a 10% SDS–polyacrylamide gel, separated by
electrophoresis and electrotransferred to a polyvinyli-
dene difluoride (PVDF) membrane. Non-specific binding
was blocked by incubating the PVDF membrane with
10 mM TBS, 1.0% Tween, and 10% dehydrated skimmed
milk. Following the blocking procedure, the membranes
were incubated overnight with antibodies against NK-1R
(1:1000) (Abcam, ab75516, UK) in 4°C. The performance
of immunoblotting on the same membranes using anti-
bodies against GAPDH (Beyotime, Shanghai, China) wasused as a loading control to assess the group differences.
Gray-value of respective well in image strip was analyzed
by software (Image J, NIH, USA) and normalized to
value of GAPDH. Data of each group was acquired by
three times of experiments at least.
Results
Samples and blood index acquired from separate groups
were shown in Table 1. Mean ages were 28.5 and 40.4 years
in groups of DDH and DDH&OA respectively. Significant
differences in serum CRP, ESR as well as VAS and HHS
were observed in comparisons among DDH, DDH&OA
and Control group.
Change of SP levels in serum and synovium
SP in serum
Concentrations of serum SP in patients from different
groups were presented in (Figure 1A, C-D). From
(Figure 1A), significantly higher levels of SP could be
observed in group of DDH and DDH&OA compared
to control group (P < 0.05). Furthermore, SP levels in
DDH&OA group show obvious difference compared to
that in DDH group. Additionally, we did not obtain sig-
nificant differences of serum SP levels between male and
female in each group (Figure 1C-D).
SP in synovium
To identify the concentration of SP in synovial tissue of
hip joint, and to the possible sources of SP, we adopted the
two-step extraction method which has been described
above. According to the outcome of ELISA (Figure 1B), SP
is found both in the first and second extraction which
stands for free nerve endings (neuronal) and non-neuronal
tissues respectively. According to the remarkable diffe-
rence of SP levels between the first and second extraction
in DDH&OA (Figure 1B), we could speculate that the
production of SP in synovium was mainly secreted from
peripheral neuron which present as the first extraction.
Moreover, from the first and total extraction from syno-
vium, we could get significantly higher SP levels in
DDH&OA than that in DDH.
Correlation of SP in serum with VAS, HHS and ESR in
patients among different groups
As expected, patients in DDH&OA group had obvious
higher score in VAS (P < 0.05) but lower score in HHS
(P < 0.01) compared to that in DDH group. In the correl-
ation detection (Table 2), significant positive correlations
were found in group of DDH&OA (Female +Male): SP/
HHS: r = −0.496, P < 0.01; SP/VAS: r = 0.512, P < 0.01.
DDH&OA (Male): SP/HHS: r = −0.694, P < 0.01. DDH
(Male): SP/HHS: r = −0.82, P < 0.01. Furthermore, we also
observed a strong correlation of SP in serum with ESR
Figure 1 Levels of substance P in both serum and synovium from patients among different groups. (A) Contents of SP in serum by an
ELISA assay. Serum samples were obtained from patients with DDH (n = 40), DDH&OA (n = 40) and normal people (n = 31) recruited in this
research. (B) Concentration of SP levels in synovial of fossa acetabuli from patients in separate groups. 1 extraction stands for SP secreted from
free nerve endings in synovial tissue, whereas 2 extraction means SP generated from non-neuronal cells (*P < 0.05). (C)-(D) Gender differences of
serum SP levels was investigated in each group (*P < 0.05).
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NK-1R is up-regulated in synovial tissue of patients with
DDH&OA compared to DDH
According to (Figure 2D-F), we can observe significantly
intensive staining of NK-1R in DDH&OA compared to
that in DDH. Besides, staining of NK-1R mainly located in
synovial cells as well as capillary vessel wall cells. In
addition, western-blot and gray analysis reflected obviouslyTable 2 Correlation test of serum SP levels with HHS, VAS
and ESR in patients with DDH and DDH&OA
Correlation of serum substance P levels
Group Sex N With HHS With VAS With ESR
R P R P R P
DDH
F 30 −0.344 0.063 0.216 0.251 0.086 0.652
M 10 −0.820 <0.01* 0.591 0.072 0.407 0.243
F + M 40 −0.219 0.175 0.349 0.027 0.156 0.336
DDH&OA
F 27 −0.384 0.048 0.355 0.069 0.497 0.083
M 13 −0.694 <0.01* 0.428 0.144 0.437 0.135
F + M 40 −0.496 <0.01* 0.512 <0.01* 0.508 <0.01*
F female, M male, N number, R correlation coefficient. Spearman correlation
test was implemented to investigate the possible correlations in separate
groups. A two sides *P < 0.01 means significant correlation.up-regulated NK-1R levels in DDH&OA group com-
pared to that in DDH group (Figure 3A-B). Similarly,
through QRT-PCR, we also witnessed analogical ten-
dency about the mRNA expression of NK-1R in these
groups (Figure 3D).
SP expression in synovial tissue
IHC staining as well as QRT-PCR were implemented to
detect the expression of SP in synovium of hip joint.
According to IHC staining and gray value analysis
(Figure 2A-C), positive staining of SP was mainly ob-
served in silk-like and nerve bundle-like nerve endings
in synovium. And we can easily get stronger staining of
SP in DDH&OA compared to DDH group. So it is with
the comparison of mRNA expression of SP from syn-
ovial tissue between these groups (Figure 3C).
Discussion
It is extensively accepted that, in advanced cases of DDH,
which frequently combined with severe degeneration and
osteoarthritis, severe pain sensation and dysfunction in
hip joint would always be the primary complaint [31,32].
Current studies have focused mainly on the members of
tachykinin family as well as its roles in the pain creation of
osteoarthritis. Besides, the relationship between neuropep-
tides and cytokines in joint fluid and serum of patients
with OA or RA were also studied [33,34]. Moreover, BN/
GRP and SP in both serum and synovial fluid were found
Figure 2 IHC staining and gray value analysis of substance P and NK-1R in human synovial of fossa acetabuli. (A-B: IHC of SP), (D-E: IHC
of NK-1R). Representative images are from patients with DDH (A and D); DDH&OA (B and E). (C and F) stands for gray value analysis of the IHC
staining (*P < 0.05). Scale bars: (A-B) 400 times magnified; (D-E): 100 times magnified. Thin arrows in (A-B) represent positive staining of nerve
fibers-like SP. Thick arrows in (B) indicate nerve bundles-like SP. Thin arrows in (D-E) display fibers-like staining of NK-1R. Thick arrows in (D) show
perivascular located staining of NK-1R.
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in patients with RA in hip joint [35]. These observations
indicated that, as a typical nerve tachykinin, SP as well as
some of the other neuropeptides might associated with in-
flammation and degeneration in hip joint and may also
have some relationships with the occurrence of pain
sensation.
In our study, the level of nerve tachykinin SP is up-
regulated in both serum and synovial tissue from pa-
tients with DDH&OA compared to that in patients with
DDH. Through serum test, we also observed some po-
sitive relationship between SP and ESR. These findings
suggest that SP might reflect somatic pain sensation toFigure 3 Protein and mRNA expression levels of NK-1R and SP in syn
groups. (A), (B): Western-blot analysis for NK-1R production levels in DDH
NK-1 in synovial tissues of separate groups. Relative gene expression was nsome extend and associate with the severity of inflam-
mation. As we know, SP along with other neuropeptides
can stimulate the release of inflammatory mediators
such as IL-1, IL-6, IL-8, and TNF-α from both blood
monocytes as well as fibroblast-like synoviocyte (FLS) in
human body [36-38]. Moreover, SP may favor the gener-
ation of memory Th17 cells by inducing IL-1β, IL-23,
TNF-like 1A expression by monocytes [39]. These me-
diators on the one hand could act as chemoattractant
molecule for further leucocyte migration. On the other
hand, they might also directly bring about inflammatory
response of the target cells through corresponding re-
ceptors and up-regulate the production of PGE2 fromovial tissue of fossa acetabuli from patients in DDH and DDH&OA
and DDH&OA groups. (C), (D): Relative mRNA expression of SP and
ormalized to the housekeeping gene GAPDH (*P < 0.05).
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and pain [40].
In our study, NK-1R, the specific receptors of SP,
revealed strong and visible immune-staining tendency in
synovial tissue from varied stages of DDH group. Previous
studies have proved that inflammatory reactions in re-
sponse to an immune irritation are strengthened in neuro-
pathic animals and are partly mediated by NK-1R [41-43].
Therefore, in this study, the up-regulated expression of
NK-1R probably reflected a feedback, inducing series of
intracellular signaling mechanisms to fit the negative stim-
uli outside. Also, researches demonstrated the validity of
NK-1R antagonists in relieving cutaneous orofacial in-
flammatory pain and reducing hyperalgesia and cartilage
destruction in the inflammatory joint in rats with adju-
vant-induced arthritis [44,45]. Herein, we might hold the
hypothesis that NK-1R antagonists could have therapeutic
value in the treatment of pathological changes and the
relief of arthritis evolvement in patients with DDH.
We know that SP stems from both neuronal and non-
neuronal cells such as fibroblasts and some immune cells
within the synovial tissue. According to the comparisons
from tissue ELISA [Figure 1B], we speculate that SP in
synovial tissue might mostly derived from segregation
of peripheral free nerve endings, which coincided with
that of previous research [46,47]. As neuropeptides were
mainly secreted from DRG and transmitted through peri-
pheral free nerve fibers, our findings indicated that more
nerve fibers might invade into synovial tissue with
the progress from DDH to DDH&OA, which probably
involved in the upgrading of inflammation and pain
sensation.
Several limitations also existed in this study. Firstly, it
is impossible to obtain perfectly normal synovial speci-
mens according to medical ethics requirement. Secondly,
the age of patients in these groups was as close as pos-
sible. In our research, the mean age of DDH&OA group
was 40.4 years, while the average age of patients with
DDH was 28.3 years. We know that SP levels in tissue
could change with ages [48,49]. Hence, doubtlessly, age
differences between groups could affect the results.
However, previous research has proved that SP levels in
both animals and human may decrease with age [50,51].
In our study, patients in group of DDH&OA who were
older than group of DDH represented higher levels of
SP in both serum and tissue, which further certified that
SP levels increase conspicuously in DDH&OA group
compared to DDH group.
Conclusions
In summary, our data firstly demonstrate that SP levels in-
creased in serum of patients with DDH. Further increase
of SP levels was observed in serum and synovial tissue,
along with the progression from DDH to DDH&OA. Thisincrease might cope with the dysfunction of hip joint as
well as the upgrade of pain sensation. These findings to-
gether with previously published investigation, suggest
that SP might associate with the creation of chronic pain
and the inflammation progress of hip joint in DDH. SP
along with its receptors NK-1R might become a promising
therapy target for future drug research in relieving the
progress of pain sensation and arthritis severities in DDH.
However, how SP involved in the progression of arthritis
and its possible bio-mechanisms performed on the dege-
neration of cartilage and subchondral bone in DDH still
need further exploration.
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